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Background: Palivizumab provides passive immunity for respiratory syncytial virus 
(RSV), but poor adherence compromises protection. A hospital initiative promoted 
administration of first palivizumab doses at an outpatient clinic immediately after 
discharge. The objectives of this study were to evaluate the impact of the initiative on 
location and timing of first palivizumab dose, patient adherence, reimbursement, 
acquisition cost and RSVpositive hospital readmissions. 
Methods: This retrospective cohort study included pediatric patients who received 
palivizumab from 2012 to 2016. Three groups were compared: “before initiative,” 
“transition” and “after initiative.” Patients who did not qualify for palivizumab or who 
were eligible for palivizumab in previous RSV seasons were excluded. Multivariable 
logistic and linear regressions adjusted for patients’ characteristics were used in outcome 
analysis.  
Results: After adjusting for patients’ characteristics, there was a 13.5-fold (95% 
confidence interval: 5.9–30.5, P < 0.0001) increase in odds that patients would receive 
outpatient administration of palivizumab and 2.7-fold (95% confidence interval: 1.3–5.7, 
P = 0.0103) increase in odds of receiving the second dose within 35 days after initiative 
implementation compared with before. Although there was no significant difference 
in reimbursement percentage after initiative implementation (32% ± 30% after initiative 
and 31% ± 22% before), calculated palivizumab acquisition costs were 20.8% lower. 
RSV readmissions were not significantly different. 
Conclusions: Implementation of an initiative with defined workflow, multidisciplinary 
collaboration, and early case management efforts to obtain insurance authorization 
increased outpatient administration of first palivizumab doses. Patient adherence 
improved as demonstrated by more timely receipt of the second palivizumab dose. There 
was no difference in reimbursement; however, acquisition cost decreased which is 
valuable considering low reimbursement rates. RSV-positive readmissions did not 
change significantly. 
 
 
It is estimated that approximately 2.1 million children less than 5 years of age 
require medical attention for acute respiratory tract infections caused by respiratory 
syncytial virus (RSV) each year.1 Approximately 25% of these patients visit the 
emergency department, and 3% are hospitalized.1 Palivizumab is an RSV F protein 
inhibitor monoclonal antibody approved by the Food and Drug Administration to provide 
passive immunity for the prevention of serious lower respiratory tract disease caused by 
RSV in children at high risk.2,3 Palivizumab is available as a single-dose vial without 
preservatives.2,3 The average wholesale price of a 50-mg vial of Synagis (MedImmune, 
Gaithersburg, MD) was $1797.96 USD as of October 2017.4 Variations in acquisition 
costs and reimbursement may affect the financial impact of providing this expensive 
medication to patients. 
Palivizumab is indicated for patients at “high risk” for RSV disease. The 
American Academy of Pediatrics (AAP) has published guidelines for determining which 
children are at increased risk.2,5 The 2 most recent AAP guidelines, published in 2012 and 
2014, recommend that hospitalized infants who qualify for palivizumab prophylaxis 
during the RSV season receive the first dose 48–72 hours before discharge or promptly 
after discharge.5,6 Up to 5 monthly intramuscular injections are recommended during the 
RSV season.2,5,6 Children who receive the first-dose inpatient have incomplete protection 
if they do not obtain insurance approval and receive subsequent doses postdischarge. 
Several studies have shown that patients who are fully compliant with the recommended 
prophylaxis have decreased risk of RSV-associated hospitalizations. 7–9 
This institution implemented a palivizumab utilization initiative designed to help 
patients navigate the healthcare system to obtain prophylaxis after hospital discharge; 
additionally, the initiative promoted administration of the first dose in an associated 
outpatient clinic on the day of discharge. The primary objectives of this study were to 
evaluate the impact of the initiative on location and timing of the first palivizumab dose 
administration, patient adherence, acquisition cost and reimbursement. The secondary 
objective was to evaluate RSV-positive hospital readmissions. 
 
MATERIALS AND METHODS 
 
Utilization Initiative 
 
The outpatient clinic associated with this pediatric hospital has historically 
provided a venue for patients to receive monthly palivizumab injections. Before the 
initiative implementation, most patients admitted to the hospital who qualified for 
prophylaxis received the first dose in the hospital, before discharge. 
Late in the 2014 to 2015 RSV season, the hospital implemented an initiative 
designed to assist patients who qualified for palivizumab prophylaxis navigate the 
healthcare system and obtain prophylaxis after discharge (Fig. 1). Case managers 
reviewed patient eligibility as soon as possible after admission and provided proactive 
assistance to obtain insurance authorization and establish follow-up at the clinic or 
another insurance-approved provider. Additionally, the initiative aimed to promote 
administration of the first prophylaxis dose in the clinic because of anticipated improved 
acquisition cost and more favorable financial reimbursement. Acquisition cost was 
expected to be lower in the outpatient setting because of availability of the 340B Drug 
Pricing Program. Inpatient reimbursement was expected to be less favorable because of 
per diem payment models. 
A workflow within the electronic medical record allowed case managers to 
propose an order to a physician for prompt referral to the hospital-associated clinic (Fig. 
1). The physician reviewed and co-signed the orders for patients who qualified. Upon 
receipt of this electronic referral, the clinic coordinator initiated a request for insurance 
authorization. If insurance providers declined to cover palivizumab administration in the 
clinic, the hospital case manager requested authorization for a site designated by the 
insurance, facilitated scheduling of an appointment and communicated appointment 
information to the family and provider. If authorization was obtained for dosing in the 
clinic, an appointment was scheduled for the day of discharge, the charge nurse followed 
up to confirm the appointment, and the patient was escorted by a nurse to the clinic upon 
discharge. In the clinic, palivizumab was administered, education was provided and the 
next appointment was scheduled. If insurance authorization was not obtained before 
discharge, qualifying patients could receive an inpatient dose. In the event of discharge 
when the clinic was closed (evenings, weekends or holidays), dosing could occur in the 
clinic on the next available clinic day or inpatient before discharge. During the 2015 to 
2016 season, case managers proactively utilized this workflow to coordinate palivizumab 
prophylaxis and communicate with patients and caregivers. 
The hospital promoted adherence to the most current AAP guidelines for 
palivizumab prophylaxis. Palivizumab 15 mg/kg was administered intramuscularly. 
Clinical pharmacists reviewed all inpatient orders for palivizumab to verify qualification 
per the AAP guidelines. Doses which did not meet guidelines criteria required approval 
from physicians who specialize in infectious disease or pulmonology. 
 
Study Design and Population 
 
This retrospective study evaluated a cohort of pediatric patients who received 
palivizumab at a 279-bed pediatric hospital or the associated outpatient clinic located on 
the hospital campus between September 1, 2012, and April 30, 2016. Because of the 
development and implementation of the initiative workflow over the course of the 2014 
RSV season, without a defined implementation date, this season was considered a 
transition period. Therefore, 3 groups were compared: “before initiative” (2012 to 2013 
and 2013 to 2014 RSV seasons), “transition” (2014 to 2015 RSV season) and “after 
initiative” (2015 to 2016 RSV season). 
All palivizumab doses given at the hospital or clinic were identified through the 
electronic medical record. Patients who received their first dose of palivizumab during a 
hospital admission or who were discharged during the RSV season (November through 
April) before their first dose were included in the study. The focus of the initiative was to 
help patients navigate the healthcare system; therefore, only patients ≤7 months of age at 
the start of the RSV season were included. It was anticipated that patients older than 7 
months of age were eligible for palivizumab in the previous RSV season and had 
established insurance coverage and primary care providers. Patients who did not need a 
dose at the time of discharge were excluded (eg, patient received a previous dose and was 
not due for the next dose, or patient was transferred to another inpatient institution). 
Patients who did not qualify for palivizumab per the AAP guidelines for that season were 
excluded. Records were not available to identify patients who received the first 
palivizumab dose at an alternate location because of insurance denial; therefore, 
these patients were excluded. Fig., Supplemental Digital Content 1 
(http://links.lww.com/INF/D71) illustrates the patient selection criteria. 
This study was approved by the Institutional Review Board and granted a waiver 
of informed consent requirements. Patients who received palivizumab were identified 
through the electronic medical record. Data collected from the electronic medical record 
included the patient weight, age, gender, indication for palivizumab and insurance 
coverage at the time of the first dose. The dose, location and timing of palivizumab 
administration; charge and reimbursement; and timing of hospital discharge were 
recorded. Hospital admissions with a positive RSV laboratory result after palivizumab 
receipt and total RSV-positive admissions for each season were determined. 
 
 
FIGURE 1. Palivizumab utilization initiative workflow. 
 
Outcomes 
 
Primary outcomes included location and timing of the first dose of palivizumab, 
patient adherence and reimbursement. To evaluate the location and timing, outcomes 
included the percentage of doses administered in the outpatient clinic and the percentage 
of outpatient doses given on the day of discharge. 
Adherence was evaluated by 3 methods and only included patients who were 
considered eligible for a second dose during the same RSV season. Patients receiving 
their first dose in March or April were excluded. Data were not available for doses given 
at an outside provider. First, the percentage of patients who received the second dose ≤35 
days after the first dose was compared for all patients. Second, the interval in days 
between first and second doses was compared. Only patients who received a second dose 
at the hospital or associated clinic were included in the analysis of dosing interval. Third, 
receipt of expected remaining doses for the season was evaluated. The expected number 
of doses was calculated based on month of hospital discharge in relation to the RSV 
season, assuming that doses were due beginning at discharge and continuing monthly 
through March. For example, a patient discharged in November would be expected to 
receive 5 doses, but a patient discharged in January would only be expected to receive 3 
doses. For all patients, the expected number of doses was determined and compared with 
actual receipt. 
The outcome measure for reimbursement analysis was the percentage of the 
charge for palivizumab that was reimbursed. Reimbursement data were only available as 
a percentage of total visit charges; therefore, reimbursement was assumed to be equally 
distributed. For example, if 45% of total visit charges were reimbursed, then it was 
assumed that 45% of the palivizumab charge was reimbursed. Overall reimbursement for 
inpatient doses compared with outpatient doses was also evaluated. 
A calculation was performed to determine the difference in acquisition cost per 
initial dose dispensed before and after initiative implementation, based upon the 
following assumptions: (1) Wholesale acquisition cost and 340B Drug Pricing Program 
cost were applied to inpatient and outpatient doses, respectively. (2) Costs from the end 
of the study period were applied to all doses to eliminate inflation. (3) It was assumed 
that all inpatient doses given on the same day were prepared in a batch to minimize vial 
waste; therefore, the sum of inpatient doses each day was rounded up to the nearest 50 
mg vial increment. 
The secondary outcome was RSV-positive hospital admissions after receipt of 
palivizumab. An RSV-positive admission was defined as an admission at this hospital 
with a positive laboratory test result for the detection of RSV antigen during RSV season. 
The number of RSV-positive admissions to this hospital following palivizumab receipt 
and the total number of RSV-positive admissions was determined for each season. 
 
Statistical Analysis 
 
Descriptive statistics were calculated. χ2 tests or Fisher exact tests were used to 
assess the difference in categorical outcomes, while 1-way analysis of variance tests were 
used to test the homogeneity of continuous outcomes across the 3 initiative 
implementation groups. Wilcoxon-Mann-Whitney test was used to evaluate differences in 
reimbursement for inpatient or outpatient dosing. 
Multivariable logistic regressions were used to evaluate the location of first-dose 
administration, adherence of second dose and adherence to remainder of prophylaxis 
course, adjusting for patients’ characteristics of gender, age, weight, dose and type of 
insurance. Multivariable linear regression was used to evaluate the interval between first 
and second doses and to assess the relationship between reimbursement and initiative 
implementation, adjusting for patients’ characteristics of gender, age, weight, dose and 
type of insurance. 
Patients receiving their first dose in March or April were excluded from the 
analysis of adherence for subsequent doses. These patients were not expected to receive 
additional doses. Patients who did not receive a second dose at this institution or the 
associated outpatient clinic were excluded from multivariable linear regression analysis 
of interval in days between first and second dose. 
SAS version 9.4 procedures FREQ, ANOVA, GLM and LOGISTIC (SAS 
Institute, Cary, NC) were used for analysis. Two-sided tests with P < 0.05 were 
considered statistically significant. 
 
 
 
RESULTS 
 
Over 4 RSV seasons, 386 initial doses of palivizumab were evaluated. Patient and first-
dose characteristics for “before initiative,” “transition” and “after initiative” groups are 
presented in Table 1. Of the 386 patients included in the study, 242 patients were in the 
“before initiative” group (62.7%), 82 patients were in the “transition” group (21.2%) and 
62 patients were in the “after initiative” group (16.1%). Qualifying AAP guidelines 
criteria could not be evaluated for differences across implementation groups because 
of a change in guidelines in 2014. 
 
 
*P values for continuous variables are from 1-way analysis of variance tests; P values for 
categorical variables are from χ2 tests; and P value for insurance is from Fisher exact test. 
†Patients were not considered eligible for a second dose if they received the first dose in 
March or April. 
SD indicates standard deviation. 
 
 
After adjusting for patients’ characteristics, there was a 13.5-fold [95% 
confidence interval (CI): 5.9–30.5, P < 0.0001] increase in odds that patients would 
receive the initial palivizumab dose in the clinic after initiative implementation compared 
with before (Fig. 2). Patients who were privately insured were 57% [odds ratio (OR) = 
0.4, 95% CI: 0.2–0.8, P = 0.003] less likely to receive the first dose in the clinic than 
patients with public insurance. Patients who received their first palivizumab dose in 
the clinic had a 3.1-fold (95% CI: 1.2–8.0, P = 0.0227) increase in odds of receiving that 
dose on the day of discharge after initiative implementation compared with before. None 
of the other patient characteristics evaluated in multivariate logistic regression had a 
significant impact. 
Adherence was evaluated by 3 methods. After adjusting for patients’ 
characteristics, patients had a 2.7-fold (95% CI: 1.3–5.7, P = 0.0103) increase in odds of 
receiving their second palivizumab dose at the clinic within 35 days after initiative 
implementation compared with before (Fig. 3). Privately insured patients were less likely 
to receive their second dose within 35 days compared with patients with public insurance 
(OR = 0.6, 95% CI: 0.3–0.9, P = 0.0259). Additionally, among patients who returned for 
a second dose at this hospital or clinic, the interval between first 2 doses was 4.5 days 
(95% CI: −8.7 to −0.2, P =0.0393) shorter after initiative implementation compared with 
before initiative implementation after adjusting for patients’ characteristics. The average 
number of days between the first 2 doses was 36.5 ± 13.9 days before the initiative and 
30.4 ± 3.6 days after the initiative. Finally, patients had a 2.5-fold (95% CI: 1.3–4.6, 
P = 0.0038) increase in odds of receiving the remainder of the expected prophylaxis 
course without missing any doses in the transition period compared with before initiative 
(Fig. 3); however, the increase after initiative implementation was not statistically 
significant (OR = 1.6, 95% CI: 0.8–3.1, P = 0.1808). None of the other patient 
characteristics evaluated significantly influenced adherence. 
There were no significant differences among the 3 initiative implementation 
groups for percentage of palivizumab charge reimbursed. The average reimbursement for 
all doses was 31% ± 23% (32% ± 30% after initiative implementation and 31% ± 22% 
before). Two patients who did not have private or public insurance were excluded from 
multivariable linear regression analysis of reimbursement. These patients were classified 
as self-pay for insurance status. There was no significant difference in reimbursement 
between doses administered in the hospital or outpatient clinic. The average 
reimbursement was 31% ± 22% for inpatient doses and 29% ± 24% for outpatient doses. 
Although no differences in reimbursement were found, an overall decrease in acquisition 
cost was observed. In addition to decreased total acquisition cost, the acquisition cost per 
initial palivizumab dose dispensed was calculated to be 20.8% lower after initiative 
implementation than before, assuming batching of doses and pricing associated with 
administration location. 
According to Fisher exact test, RSV-positive readmissions to this hospital after 
palivizumab receipt were not significantly different among the 3 groups (Fig. 4). Five 
patients were readmitted with RSV-positive laboratory tests at this institution after receipt 
of palivizumab: 2 patients before initiative implementation, 2 patients in the transition 
year and 1 patient after initiative implementation. The total number of admissions with a 
positive RSV laboratory test at this institution for each season were as follows 
(irrespective of palivizumab receipt): 458 admissions in 2012 to 2013 RSV season, 276 
admissions in 2013 to 2014 RSV season, 426 RSV admissions in 2014 to 2015 RSV 
season and 305 in 2015 to 2016 RSV season. 
 
 
FIGURE 2. Percentage of first palivizumab doses administered in outpatient clinic. 
 
FIGURE 3. Patient adherence for subsequent doses in palivizumab prophylaxis regimen. 
 
 
 
 
 
 
FIGURE 4. RSV-positive hospital admissions. 
 
 
DISCUSSION 
 
According to a recent survey, the most frequently reported obstacles to RSV 
prophylaxis included parental refusal, unclear eligibility criteria and lack of or 
insufficient insurance.10 The initiative implemented at this institution promoted early case 
management efforts to clarify eligibility and establish insurance authorization, 
with a goal of assisting patients to obtain prophylaxis after discharge. Additional goals of 
the initiative included improved acquisition cost and financial reimbursement. 
Many hospitals administer the first dose of palivizumab prophylaxis before 
discharge, and subsequent doses are given in the outpatient setting.10 Although most 
patients at this institution received their first dose before discharge before the initiative 
was implemented, the primary administration location shifted to the outpatient clinic after 
implementation. An analysis of the palivizumab authorization process in the North 
Carolina Medicaid program indicated that the average number of days to coverage 
determination for authorization requests was 8.5 days (standard deviation = 15.4) for all 
claims and 18.4 days (standard deviation = 12.7) for claims that were escalated for 
additional medical review.11 Considering the time required to confirm coverage, early 
case management efforts and collaboration with the outpatient clinic are critical 
components in establishing authorization before discharge. 
In a global survey, the most commonly identified reasons for noncompliance 
included inconvenience, cost and lack of caregiver understanding.12 In this study patient 
adherence improved after the initiative implementation, as seen by an increased 
percentage of patients receiving their second dose within 35 days of initial dose 
and decreased interval in days between the first 2 doses administered at the hospital-
associated clinic. Increased administration of first doses in the clinic may have improved 
timely receipt of subsequent doses because of the convenience of established eligibility 
and insurance authorization before discharge, familiarity with the clinic location and 
procedures and a scheduled follow-up appointment. 
Privately insured patients were less likely to receive their first dose in the clinic or 
a second dose at the clinic within 35 days of initial dose compared with patients with 
public insurance. These differences may be reflective of restrictions from some insurance 
companies, which prevented authorization at the clinic. Multivariate logistic regression 
was used to adjust for patient characteristics, including type of insurance, to account for 
these differences during analysis of adherence. 
Several studies have examined the number of patients who received all 
palivizumab doses within 35 days of the previous dose. Lundeen et al11 found that 62.8% 
of patients with Medicaid received all of their palivizumab doses within 35 days. Based 
upon data from a large United States registry, Frogel et al8 found that 65.2%–69.5% of 
patients received each dose within 35 days. Chan et al7 determined that 72% of patients in 
a large Canadian registry received all doses within 35 days. The percentage of patients 
who received the first 2 doses of palivizumab within 35 days at this institution was 
initially much lower than these reported adherence rates; however, after initiative 
implementation, the adherence rate for timely administration of first 2 doses at this 
institution improved significantly from 47.3% to 77.8%. 
More patients in this study received all expected doses at the hospital-associated 
clinic during the transition period (70.4%) compared with before initiative (50.0%). After 
initiative implementation, the full prophylaxis course adherence rate (63%) showed a 
trend of improvement, but was not statistically significant. There is a range of adherence 
rates for receipt of full prophylaxis course reported in the literature. Lundeen et al,11 
Frogel et al8 and Chan et al7 reported that 61.1%, 79.9% to 82.7%, and 81% of patients 
received all expected doses, respectively. After implementing a program to improve 
education on AAP guidelines and establish approval at a single clinic, Afghani et al13 
found that 71% of patients received all expected doses. Stewart et al9 reviewed private 
insurance claims and found that 75% of the patients received all doses. The highest 
adherence rates were reported by studies with multi-center data, which may increase 
ability to evaluate subsequent doses. 
Overall, the percentage of patients at this institution who received a full course of 
prophylaxis without missed doses was lower than the percentage of patients who received 
their second dose within 35 days of the first dose. Other studies have also found 
decreasing adherence rates over the course of the RSV season.7 Additional methods to 
sustain adherence would be beneficial. 
In a literature search, no other studies were found that compared reimbursement 
for inpatient and outpatient administration of palivizumab. Reimbursement did not 
change significantly with the initiative implementation and shift toward outpatient 
administration; however, there was a cost savings benefit to the healthcare system in the 
form of decreased acquisition costs. This decreased cost is reflective of lower 340B 
Program pricing available in the outpatient setting. The average reimbursement was low 
across all implementation groups; therefore, the potential for decreased acquisition cost is 
valuable. 
Several studies have evaluated RSV hospitalizations after palivizumab receipt. 
Frogel et al8 found that RSV hospitalization after prophylaxis ranged from 0.7% to 2.9% 
over 4 RSV seasons. Stewart et al9 determined that 3.3% of patients who received 
palivizumab had an RSV hospitalization, and noncompliant patients had a higher rate of 
hospitalization than compliant patients (6.1 per 100 infant RSV seasons vs. 2.8 per 100 
infant RSV seasons; P < 0.001). Chan et al7 also reported a higher RSV hospitalization 
rate for nonadherent patients compared with adherent patients (1.6% and 1.2%, 
respectively). 
This study evaluated RSV hospitalizations among implementation groups to see if 
administering the first palivizumab dose in the clinic resulted in benefit because of 
improved follow-up or harm because of delayed administration. The differences in 
readmissions were not significant based upon Fisher exact test. Further multivariate 
regression analysis to account for the RSV season severity could not be performed 
because of the low incidence for this outcome. RSV incidence rates for this study were 
similar to those reported in the literature and did not significantly increase with initiative 
implementation. 
The AAP currently recommends giving the initial palivizumab dose 48–72 hours 
before discharge or promptly after discharge. 5 The initiative workflow implemented at 
this hospital aimed to provide the initial dose to patients immediately after discharge. 
While the percentage of doses given on day of discharge increased significantly with 
initiative implementation, some patients received doses after the day of discharge. 
Hospital discharges during evening, weekend or holiday hours may account for this 
delay. 
This study had limitations because of the retrospective, single-center design. 
There were no data available to identify patients who received the first palivizumab dose 
at an outside provider because of insurance denial for the hospital-associated clinic; 
therefore, these patients were not included in the study. For patients included in the study, 
if subsequent doses were not received at the clinic, it was assumed that the patient was 
nonadherent; however, the patient may have elected to receive subsequent doses at 
another provider. It is likely that most of the patients who qualified for palivizumab 
would follow-up in the clinic because the pulmonologists and cardiologists that treat 
patients in the hospital often continue to treat the patients in the clinic after discharge. 
Additionally, there were no readmission data available if the patient was admitted to an 
outside hospital. 
The AAP guidelines for palivizumab prophylaxis changed in 2014, resulting in a 
decrease in absolute number of doses and simplifying the qualification criteria.5,6 This 
study evaluated outcomes as a percentage of qualifying patients to account for the 
change in AAP guidelines and variation in number of qualifying patients. However, it is 
possible that the increased familiarity of staff with guidelines and workflow over time, 
the absolute decrease in qualifying patients or the simplified AAP guidelines criteria may 
have improved the ability to manage patients who did qualify.  
Also among the changes in the AAP guidelines published in 2014, premature 
infants with gestational age ≥29 weeks no longer qualified for palivizumab based on 
gestational age alone.5,6 This difference in the guidelines may have contributed to the 
differences in baseline weight and age. Less premature patients, who may have earlier 
hospital discharge and initial palivizumab dose at a younger postnatal age, no longer 
qualified for prophylaxis after initiative implementation. Multivariate regression was 
used to adjust for these differences. 
Ability to evaluate RSV readmissions was limited by the low incidence of RSV-
associated readmission after palivizumab receipt, lack of data from outside providers and 
provider discretion for RSV testing. Future studies would be needed to confirm these 
findings. 
Overall, implementation of a utilization initiative with defined workflow, 
multidisciplinary collaboration and early case management efforts to initiate palivizumab 
insurance authorization requests can benefit patients. Collaboration with the outpatient 
clinic and proactive efforts of inpatient case managers resulted in improved adherence for 
subsequent doses and did not increase RSV-associated admissions. Although there was 
no difference found in reimbursement rates, outpatient acquisition costs may be lower for 
some institutions. If a decreased acquisition cost can be achieved with initial doses 
administered in the clinic, this is a valuable benefit considering the low reimbursement 
rates. Future studies with the ability to incorporate data from outside providers would be 
valuable to further evaluate adherence and RSV readmission rates. 
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